October 3rd, 2019
With five biotech IPOs on the calendar, this week was expected to be a big one. Three companies ended up making Wall Street debuts, raising a combined $320 million, led by Viela Bio. But two other firms didn’t like the market conditions and decided against going public for now. Here’s a recap of the week’s biotech IPO activity so far:
—Viela Bio raised approximately $150 million from its IPO. The Gaithersburg, MD, biotech said Wednesday night that it sold 7.9 million shares for $19 each, which was the low end of its planned $19 to $21 range. Viela is developing treatments for autoimmune and inflammatory diseases. Its lead therapeutic candidate, inebilizumab, is an antibody drug developed to target CD19, a protein found on the surface of B cells, which are a type of immune cell.
The company’s initial target is neuromyelitis optica spectrum disorder (NMOSD), a rare disease characterized by inflammation of the optic nerve and the spinal cord. Viela has already filed for FDA review of the drug, which is expected to receive a regulatory decision in June 2020. The company plans to use the IPO cash to fund regulatory and pre-commercialization work for inebilizumab, and to finance clinical studies testing the drug in other diseases.
Viela’s shares began trading Thursday on the Nasdaq exchange under the stock symbol “VIE.”
—Frequency Therapeutics pulled in $84 million from its IPO. The Woburn, MA, biotech sold 6 million shares for $14 apiece, which was the low end of the $14 to $16 price range it had planned.
Frequency is developing drugs for hearing loss based on research from MIT and Harvard University. The company plans to apply the IPO proceeds to Phase 2 tests of its lead drug, FX-322. A Phase 2a study is expected to start in the fourth quarter of this year; preliminary data are expected in the second half of 2020.
Frequency’s shares are expected to begin trading on the Nasdaq Thursday under the stock symbol “FREQ.”
—Aprea Therapeutics joined the public markets with an $85 million IPO. The cancer drug developer priced its offering at $15 per share, which was the midpoint of its targeted $14 to $16 price range. Aprea, which is based in Boston and has research facilities in Stockholm, Sweden, is developing drugs that reactivate the tumor suppressor protein p53, according to its IPO filing. Lead drug candidate APR-246, a small molecule drug, is being tested in blood cancers including myelodysplastic syndromes (MDS) and acute myeloid leukemia. Preliminary results from a pivotal Phase 3 test in MDS are expected in the second half of next year.
Aprea shares began trading Thursday on the Nasdaq under the stock symbol “APRE.”
—ADC Therapeutics withdrew its plans to list shares on the New York Stock Exchange, citing “adverse market conditions,” according to IPO research firm Renaissance Capital. The Switzerland-based cancer drug developer had planned to offer 8.16 million shares in the range of $23 to $26 each. ADC is developing cancer drugs called antibody drug conjugates. These drugs affix powerful cancer-killing compounds to antibodies that home in on cancer cells. ADC’s two most advanced drugs are in mid-stage testing.
—Monopar Therapeutics also cited market conditions in postponing its IPO plans, according to Renaissance Capital. The Wilmette, IL-based cancer drug developer had planned to offer 4.4 million shares priced between $8 and $10 apiece. Monopar’s lead drug, Validive, is a new formulation of the now generic blood pressure drug clonidine. Monopar is ready to start a Phase 3 study testing its drug as a way to reduce the incidence and duration of mouth sores experienced by cancer patients receiving chemotherapy and radiation treatment. The Monopar drug formulation is a tablet that the company says allows for prolonged delivery of the therapeutic to the regions of the mucus membrane damaged by cancer treatment.
Photo by Flickr user nakashi via a Creative Commons license. Photo has been cropped to fit Xconomy publishing system standards.
Frank Vinluan is editor of Xconomy Raleigh-Durham, based in Research Triangle Park. You can reach him at fvinluan [at] xconomy.com Follow @frankvinluan
本周，预计将有5家生物科技公司上市。三家公司最终在华尔街上市，筹集了3.2亿美元，由 Viela Bio 领衔。但另外两家公司不喜欢市场环境，决定暂时不上市。以下是本周迄今生物科技 IPO 活动的概要：
—— Viela Bio 通过 IPO 募集了约1.5亿美元。Gaithersburg , MD , Biotechnology 周三晚间表示，该公司以每股19美元的价格出售了790万股股票，这是该公司计划的19美元至21美元区间的低端。Viela 正在开发治疗自身免疫性和炎症性疾病的方法。它的主要治疗候选药物， inebilizumab ，是一种抗体药物开发的目标 CD19，一种蛋白质发现表面的 B 细胞，这是一种免疫细胞。
该公司最初的目标是神经脊髓炎光谱障碍（ NMOSD ），一种罕见的疾病，以视神经和脊髓发炎为特征。Viela 已经向 FDA 提交了该药物的审评申请，预计将于2020年6月获得一项监管决定。公司拟使用首次公开发行股票募集资金，用于支付去胆碱单抗的监管和商业化前工作，并为该药物在其他疾病中的临床研究提供资金。
维埃拉的股票周四开始在纳斯达克交易，股票代码为“ VIE ”。
——频率治疗公司从 IPO 中获得了8400万美元。Woburn , MA , Biotechnology 以每股14美元的价格出售了600万股股票，这是该公司计划的14-16美元价格区间的低端。
根据麻省理工学院和哈佛大学的研究，频率正在开发用于听力损失的药物。该公司计划将 IPO 募集资金用于其先导药物 FX-322的二期测试。第二阶段研究预计将于今年第四季度开始；初步数据预计将于2020年下半年开始。
预计该公司股票将于周四在纳斯达克( Nasdaq )开始交易，交易代码为“ FREQ ”。
—— Aprea Therapeutics 以8500万美元的 IPO 加入了公开市场。这家癌症药物开发商的发行价为每股15美元，这是其目标价区间14至16美元的中点。Aprea 的 IPO 申请文件显示，总部位于波士顿、在瑞典斯德哥尔摩拥有研究设施的 Aprea 正在研发能够激活肿瘤抑制蛋白 p53的药物。先导药物候选药物 APR-246是一种小分子药物，目前正在测试血液肿瘤，包括骨髓增生异常综合征（ MDS ）和急性髓系白血病。MDS 关键第3阶段测试的初步结果预计将在明年下半年公布。
Aprea 股票周四在纳斯达克开始交易，股票代码为“ APRE ”。
根据 IPO 研究公司 Renaissance Capital 的数据， ADC Therapeutics 撤回了在纽约证交所上市的计划，理由是“不利的市场条件”。这家总部位于瑞士的癌症药物开发商计划以每股23至26美元的价格发行816万股股票。ADC 正在开发称为抗体药物共轭物的癌症药物。这些药物将强大的抗癌化合物与肿瘤细胞中的抗体结合在一起。ADC 最先进的两种药物正处于中期试验阶段。
—根据复兴资本( Renaissance Capital )的说法， Monopa Therapeutics 还提到了推迟 IPO 计划的市场条件。总部位于 IL-Wilmette 的癌症药物开发商计划发行440万股每股8-10美元的股票。Monopal 的先导药物，有效，是一种新的制剂，现在通用的血压药物可乐定。Monopal 准备开始第三阶段的研究，测试其药物，以减少接受化疗和放射治疗的癌症患者口腔溃疡的发生率和持续时间。Monopal 药物制剂是一种片剂，该公司称，这种片剂可以延长治疗时间，使之进入因癌症治疗而受损的粘液膜区域。
Flickr 用户 nakashi 通过 CreativeCommons 许可拍照。照片已裁剪以适应 Xconeconomy 出版系统标准。
FrankVinluan 是 XconomicRaleigh-Durham 的编辑，位于研究三角公园。你可以在福文卢万[ xconomi ]找到他。com Follow @ frankvinluan